申请人:Sanofi
公开号:US05447931A1
公开(公告)日:1995-09-05
New therapeutic use of some heterocyclylpiperazines of formula (I) ##STR1## wherein R represents hydrogen or (C.sub.1 -C.sub.4)alkyl, R.sub.1 represents hydrogen or a methyl group, R.sub.2 represents hydrogen or a halogen atom; X et Y represent each --CH.dbd., or one is --CH.dbd. and the other is --N.dbd., as well as their pharmaceutically acceptable salts for the preparation of a medicament for the treatment or prophylaxis of the pathological conditions which can be improved by 5-HT.sub.3 mediated selective agonism and new compounds deriving from this chemical class.
化学式(I)中一些杂环哌嗪的新治疗用途。其中,R代表氢或(C.sub.1 -C.sub.4)烷基,R.sub.1代表氢或甲基基团,R.sub.2代表氢或卤素原子;X和Y分别表示--CH.dbd.,或一个是--CH.dbd.,另一个是--N.dbd.,以及它们的药用盐,用于制备治疗或预防可以通过5-HT.sub.3介导的选择性激动作用改善的病理状况的药物,以及从这种化学类别衍生的新化合物。